BioSyent (CVE:RX) Hits New 12-Month High – What’s Next?

BioSyent Inc. (CVE:RX) shares hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as C$14.49 and last traded at C$14.40, with a volume of 9479 shares changing hands. The stock had previously closed at C$13.76.

Analysts Set New Price Targets

Separately, Bloom Burton upgraded BioSyent from a “moderate buy” rating to a “strong-buy” rating in a research report on Friday, November 21st. One analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat, BioSyent currently has an average rating of “Strong Buy”.

BioSyent Price Performance

The business’s 50-day simple moving average is C$12.67 and its two-hundred day simple moving average is C$11.89. The stock has a market cap of C$163.43 million, a price-to-earnings ratio of 19.40 and a beta of 0.52. The company has a debt-to-equity ratio of 2.90, a current ratio of 3.92 and a quick ratio of 6.91.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.